{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:30:01Z","timestamp":1759332601039},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T00:00:00Z","timestamp":1276041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9590-4","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T14:01:54Z","timestamp":1276005714000},"page":"991-998","source":"Crossref","is-referenced-by-count":13,"title":["Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes"],"prefix":"10.1007","volume":"28","author":[{"given":"In Sil","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haeryoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,9]]},"reference":[{"key":"9590_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"9590_CR2","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","volume":"18","author":"U Vanhoefer","year":"2000","unstructured":"Vanhoefer U, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18:2648\u201357.","journal-title":"J Clin Oncol"},{"key":"9590_CR3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346.","journal-title":"N Engl J Med"},{"key":"9590_CR4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, et al. Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666\u201373.","journal-title":"Ann Oncol"},{"key":"9590_CR5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4143\/crt.2007.39.3.99","volume":"39","author":"IS Choi","year":"2007","unstructured":"Choi IS, et al. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res Treat. 2007;39:99\u2013103.","journal-title":"Cancer Res Treat"},{"key":"9590_CR6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/sj.bjc.6601413","volume":"89","author":"W Koizumi","year":"2003","unstructured":"Koizumi W, et al. Phase I\/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207\u201312.","journal-title":"Br J Cancer"},{"key":"9590_CR7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2005.04.2994","volume":"24","author":"JA Ajani","year":"2006","unstructured":"Ajani JA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:663\u20137.","journal-title":"J Clin Oncol"},{"key":"9590_CR8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00280-007-0541-5","volume":"61","author":"JL Lee","year":"2008","unstructured":"Lee JL, et al. Phase I\/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol. 2008;61:837\u201345.","journal-title":"Cancer Chemother Pharmacol"},{"key":"9590_CR9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"9590_CR10","first-page":"1469","volume":"4","author":"N Boku","year":"1998","unstructured":"Boku N, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998;4:1469\u201374.","journal-title":"Clin Cancer Res"},{"key":"9590_CR11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","volume":"16","author":"R Metzger","year":"1998","unstructured":"Metzger R, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16:309\u201316.","journal-title":"J Clin Oncol"},{"key":"9590_CR12","first-page":"653","volume":"17","author":"S Miyamoto","year":"2000","unstructured":"Miyamoto S. et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol. 2000;17:653\u20138.","journal-title":"Int J Oncol"},{"key":"9590_CR13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.bjc.6602139","volume":"91","author":"W Ichikawa","year":"2004","unstructured":"Ichikawa W, et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer. 2004;91:1245\u201350.","journal-title":"Br J Cancer"},{"key":"9590_CR14","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/ijc.22080","volume":"119","author":"W Ichikawa","year":"2006","unstructured":"Ichikawa W, et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927\u201333.","journal-title":"Int J Cancer"},{"key":"9590_CR15","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-04-1605","volume":"11","author":"R Napieralski","year":"2005","unstructured":"Napieralski R, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res. 2005;11:3025\u201331.","journal-title":"Clin Cancer Res"},{"key":"9590_CR16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ijc.24726","volume":"126","author":"W Koizumi","year":"2010","unstructured":"Koizumi W, et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer. 2010;126:162\u201370.","journal-title":"Int J Cancer"},{"key":"9590_CR17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.ejhg.5201884","volume":"15","author":"B Liu","year":"2007","unstructured":"Liu B, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet. 2007;15:1049\u201353.","journal-title":"Eur J Hum Genet"},{"key":"9590_CR18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","volume":"355","author":"KA Olaussen","year":"2006","unstructured":"Olaussen KA, et al. Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983\u201391.","journal-title":"N Engl J Med"},{"key":"9590_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc970","volume":"3","author":"AD D\u2019Andrea","year":"2003","unstructured":"D\u2019Andrea AD, Grompe M. The Fanconi anaemia\/BRCA pathway. Nat Rev Cancer. 2003;3:23\u201334.","journal-title":"Nat Rev Cancer"},{"key":"9590_CR20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10715769900301121","volume":"31","author":"S Goto","year":"1999","unstructured":"Goto S, et al. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res. 1999;31:549\u201358.","journal-title":"Free Radic Res"},{"key":"9590_CR21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L","volume":"92","author":"HS Lee","year":"2001","unstructured":"Lee HS, et al. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001;92:1427\u201334.","journal-title":"Cancer"},{"key":"9590_CR22","doi-asserted-by":"crossref","unstructured":"Choi IS, et al. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Med Oncol. 2010; doi: 10.1007\/s12032-009-9321-x .","DOI":"10.1007\/s12032-009-9321-x"},{"key":"9590_CR23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s101470300013","volume":"8","author":"R Fujii","year":"2003","unstructured":"Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 2003;8:72\u20138.","journal-title":"Int J Clin Oncol"},{"key":"9590_CR24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2007.01.006","volume":"252","author":"Y Kodera","year":"2007","unstructured":"Kodera Y, et al. Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 2007;252:307\u201313.","journal-title":"Cancer Lett"},{"key":"9590_CR25","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.bjc.6601335","volume":"89","author":"W Ichikawa","year":"2003","unstructured":"Ichikawa W, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003;89:1486\u201392.","journal-title":"Br J Cancer"},{"key":"9590_CR26","first-page":"2997","volume":"25","author":"T Shimizu","year":"2005","unstructured":"Shimizu T, Yamada Y, Yasui H, Shirao K, Fukuoka M. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer Res. 2005;25:2997\u20133001.","journal-title":"Anticancer Res"},{"key":"9590_CR27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000011968","volume":"56","author":"W Koizumi","year":"1999","unstructured":"Koizumi W, Saigenji K, Nakamaru N, Okayasu I, Kurihara M. Prediction of response to 5\u2032-deoxy-5-fluorouridine (5\u2032-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase\/platelet-derived endothelial cell growth factor. Oncology. 1999;56:215\u201322.","journal-title":"Oncology"},{"key":"9590_CR28","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","volume":"19","author":"Y Shirota","year":"2001","unstructured":"Shirota Y, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298\u2013304.","journal-title":"J Clin Oncol"},{"key":"9590_CR29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/annonc\/mdl430","volume":"18","author":"HC Kwon","year":"2007","unstructured":"Kwon HC, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil\/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504\u20139.","journal-title":"Ann Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9590-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9590-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:22:47Z","timestamp":1559427767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9590-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,9]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9590"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9590-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,9]]}}}